Phase III LOTUS study of Stelara in Systemic Lupus Erythematosus discontinued.- Janssen Pharma
The Janssen Pharmaceutical Companies of Johnson & Johnson announced its decision to discontinue the Phase III LOTUS study of Stelara (ustekinumab) in Systemic Lupus Erythematosus (SLE) due to… read more.